Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1937]

IKEMA: Carfilzomib and dexamethasone plus isatuximab for r/r multiple myeloma

Prof Philippe Moreau - University of Nantes, Nantes, France

IKEMA: Carfilzomib and dexamethasone plus isatuximab for r/r multiple myeloma ( Prof Philippe Moreau - University of Nantes, Nantes, France )

LOW-PV interim analysis: Ropeginterferon versus phlebotomy in low-risk...

Prof Tiziano Barbui - FROM Research Foundation, Bergamo, Italy

LOW-PV interim analysis: Ropeginterferon versus phlebotomy in low-risk polycythemia vera ( Prof Tiziano Barbui - FROM Research Foundation, Bergamo, Italy )

ANDROMEDA: Subcutaneous daratumumab plus cyclophosphamide, bortezomib and...

Prof Efstathios Kastritis - University of Athens, Athens, Greece

ANDROMEDA: Subcutaneous daratumumab plus cyclophosphamide, bortezomib and dexamethasone in newly-diagnosed AL amyloidosis ( Prof Efstathios Kastritis - University of Athens, Athens, Greece )

The NEUF study: Treatment of r/r Philadelphia chromosome-positive ALL with...

Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain

The NEUF study: Treatment of r/r Philadelphia chromosome-positive ALL with blinatumomab ( Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain )

BLIN-01: Blinatumomab for high-risk, Philadelphia chromosome-negative acute...

Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain

BLIN-01: Blinatumomab for high-risk, Philadelphia chromosome-negative acute lymphoblastic leukaemia ( Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain )

Maintenance treatment in multiple myeloma: A new era

Prof Sagar Lonial and Prof Wee-Joo Chng

Maintenance treatment in multiple myeloma: A new era ( Prof Sagar Lonial and Prof Wee-Joo Chng )

Phase II data from the KarMMa trial for relapsed/refractory multiple myeloma

Dr Nikhil Munshi - Dana Farber Cancer Institute, Boston, USA

$Phase II data from the KarMMa trial for relapsed/refractory multiple myeloma ( Dr Nikhil Munshi - Dana Farber Cancer Institute, Boston, USA )$

Pembrolizumab vs brentuximab vedotin in relapsed or refractory classic Hodgkin...

Dr John Kuruvilla - Princess Margaret Cancer Centre, Toronto, Canada

$Pembrolizumab vs brentuximab vedotin in relapsed or refractory classic Hodgkin lymphoma ( Dr John Kuruvilla - Princess Margaret Cancer Centre, Toronto, Canada )$

ASPEN: Results of a phase III randomised trial of zanubrutinib vs ibrutinib for...

Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia

ASPEN: Results of a phase III randomised trial of zanubrutinib vs ibrutinib for patients with Waldenström macroglobulinemia ( Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia )

US MM-6: Long-term proteasome inhibition in multiple myeloma following an in...

Dr Sudhir Manda - Arizona Oncology / US Oncology Research, Tucson, USA

US MM-6: Long-term proteasome inhibition in multiple myeloma following an in-class transition from bortezomib to ixazomib ( Dr Sudhir Manda - Arizona Oncology / US Oncology Research, Tucson, USA )

Regulating haematopoietic stem cell dormancy and ageing through the netrin-1...

Dr Simon Renders - German Cancer Research Center (DKFZ), Heidelberg, Germany

Regulating haematopoietic stem cell dormancy and ageing through the netrin-1-neogenin axis ( Dr Simon Renders - German Cancer Research Center (DKFZ), Heidelberg, Germany )

Enasidenib plus azacitidine vs azacitidine monotherapy in mutant-IDH2 ND-AML

Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA

Enasidenib plus azacitidine vs azacitidine monotherapy in mutant-IDH2 ND-AML ( Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA )

More from ecancer